Centessa Pharmaceuticals Announces $150M Proposed Public Offering Of American Depositary Shares
Centessa Pharmaceuticals Announces $150M Proposed Public Offering Of American Depositary Shares
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Centessa Pharmaceuticals plc（納斯達克股票代碼：CNTA）是一家臨床階段的製藥公司，旨在發現和開發對患者具有變革意義的藥物。該公司今天宣佈，它已開始承銷1.5億美元的美國存托股票（「ADS」），每股代表一股普通股。所有的ADS都由Centessa提供。此外，Centessa打算授予承銷商30天的期權，允許他們額外購買公開發行中發行的多達2,250萬美元的ADS。擬議的發行受市場和其他條件的約束，無法保證發行是否或何時完成，也無法保證發行的實際規模或條款。
Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering.
高盛公司LLC、Leerink Partners、Evercore ISI、古根海姆證券和BMO Capital Markets擔任此次發行的聯席帳簿管理人。
譯文內容由第三人軟體翻譯。